Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Mobidiag Announces Agency Agreement with YouMed for the Commercialization of its Molecular Diagnostic Product line Amplidiag® in UK

Posted on: 04 Oct 16

Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with YouMed Ltd, bespoke sales, marketing and distribution of high-quality medical technologies, regarding the Amplidiag® product line. Under this agreement YouMed becomes an agent for commercialization in UK of Amplidiag® product line, in vitro diagnostic tests and compatible system for the detection of gastrointestinal infections.

“For the past months, we have been extending significantly our European distribution network. Making our Amplidiag product line available in UK was definitely our next strategic step. Besides being clearly a high-value market, I strongly believe that our Amplidiag suite can bring great benefits to UK’s healthcare professionals. With that in mind, we are happy to initiate our partnership with YouMed as our local agent to expand Mobidiag’s market reach and visibility in UK” said Tuomas Tenkanen, CEO at Mobidiag.

“YouMed are proud and excited to be partnering with Mobidiag bringing their Amplidiag range of products to the UK healthcare market. There is an unmet need in the UK molecular diagnostic market for accurate, reliable testing for Gastro-intestinal pathogens. We are confident the Mobidiag assays and systems can have a positive impact on management of patients suffering from these infections” said Christopher Brain, Managing Director at YouMed Ltd.

The agreement is effective immediately and covers all Amplidiag® IVD tests (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE and upcoming Amplidiag® Viral GE) as well as the upcoming Amplidiag® Easy system.

About Amplidiag® assays
Amplidiag® assays are innovative multiplex tests for the detection of gastrointestinal infections. They allow to screen panels of the most relevant gastrointestinal pathogens. Based on well-established real-time PCR technology, they ensure optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings.

About Mobidiag Ltd
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Mobidiag addresses both high to medium volume screening with the new Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs.
Visit for more information.

About YouMed Ltd
YouMed is a privately owned company with significant experience in selling products and services to primary and secondary medical care sites throughout the UK and Ireland. YouMed offers products and services across a defined range of clinical areas: Diagnostics, Sports medicine, Orthopaedics and Consultancy. With wide ranging experience in the delivery of point of care, oncology, genetics and infectious disease products, YouMed ensures that high quality, innovative technology is available in the laboratory for the benefit of medical specialists and their patients.

View source version on

Business Wire

Last updated on: 04/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.